Renaissance Technologies LLC Has $328,000 Position in Nautilus Biotechnology, Inc. (NASDAQ:NAUT)

Renaissance Technologies LLC raised its holdings in shares of Nautilus Biotechnology, Inc. (NASDAQ:NAUT) by 11.2% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 140,100 shares of the company’s stock after purchasing an additional 14,100 shares during the quarter. Renaissance Technologies LLC owned approximately 0.11% of Nautilus Biotechnology worth $328,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of NAUT. Perceptive Advisors LLC grew its stake in shares of Nautilus Biotechnology by 38.2% in the fourth quarter. Perceptive Advisors LLC now owns 12,594,211 shares of the company’s stock valued at $37,657,000 after acquiring an additional 3,483,060 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its holdings in Nautilus Biotechnology by 66.6% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 24,076 shares of the company’s stock valued at $71,000 after purchasing an additional 9,624 shares during the period. Vanguard Group Inc. boosted its holdings in Nautilus Biotechnology by 1.0% in the 1st quarter. Vanguard Group Inc. now owns 2,859,402 shares of the company’s stock valued at $8,407,000 after purchasing an additional 29,604 shares during the period. Price T Rowe Associates Inc. MD grew its position in shares of Nautilus Biotechnology by 35.8% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 16,078 shares of the company’s stock worth $48,000 after purchasing an additional 4,239 shares in the last quarter. Finally, Clarius Group LLC increased its holdings in shares of Nautilus Biotechnology by 2.7% during the second quarter. Clarius Group LLC now owns 636,532 shares of the company’s stock worth $1,489,000 after purchasing an additional 16,661 shares during the period. Institutional investors own 50.71% of the company’s stock.

Analyst Ratings Changes

Separately, Guggenheim initiated coverage on shares of Nautilus Biotechnology in a report on Thursday, June 27th. They issued a “buy” rating and a $6.00 target price for the company.

Nautilus Biotechnology Stock Performance

NASDAQ:NAUT opened at $2.86 on Friday. The firm has a market capitalization of $358.67 million, a price-to-earnings ratio of -5.11 and a beta of 1.22. The stock has a fifty day moving average of $2.62 and a 200 day moving average of $2.61. Nautilus Biotechnology, Inc. has a 52-week low of $2.19 and a 52-week high of $3.45.

Nautilus Biotechnology (NASDAQ:NAUT) last announced its quarterly earnings results on Tuesday, July 30th. The company reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.02. During the same period in the previous year, the firm earned ($0.13) earnings per share. Equities analysts forecast that Nautilus Biotechnology, Inc. will post -0.65 earnings per share for the current fiscal year.

Insider Activity

In other news, VP Mary E. Godwin sold 47,031 shares of the stock in a transaction that occurred on Monday, September 23rd. The shares were sold at an average price of $2.87, for a total transaction of $134,978.97. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 40.50% of the company’s stock.

Nautilus Biotechnology Profile

Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.